The drugmaker conducted a phase 3 trial involving more than 10,000 participants ages 16 and older who received two doses of Pfizer’s COVID-19 vaccine. Half of the participants received a booster dose and half received a placebo. The median time between the second dose and the administration of the booster or placebo was about 11 months.
Participants who received a booster dose restored their immunity to the same high levels achieved after their second dose, as the research team observed the vaccine’s efficacy to be 95.6 percent among this group.
Pfizer said the results were the first to come from a randomized, controlled COVID-19 vaccine booster trial.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.